WO2014061937A1 - Pharmaceutical composition for topical administration comprising piperacillin or its salt, tazobactam or its salt and dexamethasone phosphate or its salt - Google Patents

Pharmaceutical composition for topical administration comprising piperacillin or its salt, tazobactam or its salt and dexamethasone phosphate or its salt Download PDF

Info

Publication number
WO2014061937A1
WO2014061937A1 PCT/KR2013/009020 KR2013009020W WO2014061937A1 WO 2014061937 A1 WO2014061937 A1 WO 2014061937A1 KR 2013009020 W KR2013009020 W KR 2013009020W WO 2014061937 A1 WO2014061937 A1 WO 2014061937A1
Authority
WO
WIPO (PCT)
Prior art keywords
salt
compartment
pharmaceutical composition
sodium
pharmaceutically acceptable
Prior art date
Application number
PCT/KR2013/009020
Other languages
French (fr)
Inventor
Joo-Eun Kim
Seong-Bae Park
Seung-Kwon Yang
Hyeon-Woo KANG
Myung-Young Park
Original Assignee
Yuhan Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corporation filed Critical Yuhan Corporation
Publication of WO2014061937A1 publication Critical patent/WO2014061937A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Definitions

  • the present invention relates to a pharmaceutical composition for topical administration comprising piperacillin or its salt, tazobactam or its salt and dexamethasone phosphate or its salt.
  • a pharmaceutical composition containing piperacillin (or piperacillin sodium) and tazobactam (or tazobactam sodium) is commercially available under the trademark Zosyn TM .
  • the composition which is useful for intravenous administration as antibiotics for inpatients, has a lyophilized injection form.
  • the lyophilized injection is administered by dissolving in water for injection, physiological saline, dextrose injection, etc., and the prepared solution should be used within 24 hours, at room temperature.
  • US Patent No. 6,207,661 has disclosed a premixed liquid composition comprising piperacillin sodium, tazobactam sodium, and sodium citrate as a buffer.
  • the premixed liquid composition is stored under lyophilization.
  • the stored lyophilized mixture is thawed (if necessary, a diluent is added thereto) and then parenterally administered to patients.
  • International Patent Publication No. WO2004/091666 has disclosed a pharmaceutical composition comprising piperacillin sodium; tazobactam sodium; an aminocarboxylic acid chelating agent such as ethylenediaminetetraacetic acid (EDTA) or its salt; a citrate salt as a buffer; and optionally an aminoglycoside.
  • EDTA ethylenediaminetetraacetic acid
  • dexamethasone phosphate is a corticosteroid having potent anti-inflammatory activity. Especially, dexamethasone phosphate is useful for treating allergic diseases, skin disorders, inflammatory eye disease, and otitis externa/otitis media. It has been reported that a combination therapy of an antibiotic and a steroid provides therapeutic improvement, in various researches (Baum JL, et al., Am J Ophthalmol 1974;80:513-7; Barza M.
  • a pharmaceutical formulation for topical administration containing a combination of piperacillin or its salt, tazobactam or its salt, and dexamethasone phosphate or its salt
  • the formulation requires ensuring acceptable stability in an aqueous medium such as water for injection, physiological saline, dextrose injection, over the treatment duration.
  • aqueous medium such as water for injection, physiological saline, dextrose injection
  • the present inventors carried out various researches in order to develop a stable pharmaceutical composition for topical administration comprising piperacillin or its salt, tazobactam or its salt, and dexamethasone phosphate or its salt, in which degradation product formation is minimized over the treatment duration.
  • a stabilizing agent or a buffer agent significantly affects the stability of the formulation containing piperacillin or its salt, tazobactam or its salt, and dexamethasone phosphate or its salt.
  • the present inventors found that, if piperacillin or its salt, tazobactam or its salt, and dexamethasone phosphate or its salt were formulated into a reconstitutable formulation form having two compartments (e.g., a first vial or a second plastic reservoir) along with using an acetate salt or a combination of acetic acid and its salt as a stabilizing agent, rapid reconstitution was accomplished; and also degradation product formation was minimized at the cold condition for long duration (e.g., about 2 weeks), thereby providing excellent stability.
  • two compartments e.g., a first vial or a second plastic reservoir
  • an acetate salt or a combination of acetic acid and its salt as a stabilizing agent
  • a stable pharmaceutical composition for topical administration comprising piperacillin or its salt, tazobactam or its salt, and dexamethasone phosphate or its salt as active ingredients, along with an acetate salt or a combination of acetic acid and its salt as a stabilizing agent.
  • a pharmaceutical composition for topical administration comprising piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, dexamethasone phosphate or its pharmaceutically acceptable salt, and an acetate salt or a combination of acetic acid and its salt as a stabilizing agent.
  • the pharmaceutical composition may have a unit dosage form consisting of a first compartment comprising piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, dexamethasone phosphate or its pharmaceutically acceptable salt, and an acetate salt or a combination of acetic acid and its salt as a stabilizing agent; and a second compartment comprising water.
  • the pharmaceutical composition may have a unit dosage form consisting of a first compartment comprising piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, and dexamethasone phosphate or its pharmaceutically acceptable salt; and a second compartment comprising water and an acetate salt or a combination of acetic acid and its salt as a stabilizing agent.
  • the stabilizing agent significantly affects the stability of the formulation containing piperacillin or its salt, tazobactam or its salt, and dexamethasone phosphate or its salt.
  • the present invention that, if piperacillin or its salt, tazobactam or its salt, and dexamethasone phosphate or its salt are formulated into a reconstitutable formulation form having two compartments (e.g., a first vial or a second plastic reservoir) along with using an acetate salt or a combination of acetic acid and its salt as a stabilizing agent, rapid reconstitution is accomplished; and also degradation product formation is minimized at the cold condition for long duration (e.g., about 2 weeks), thereby providing excellent stability. Therefore, the pharmaceutical composition according to the present invention can be used not only in a single administration, but also in multiple administrations for long duration along with being stored at the cold condition (i.e., 2 to 8 °C).
  • the present invention provides a pharmaceutical composition for topical administration, comprising piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, dexamethasone phosphate or its pharmaceutically acceptable salt, and an acetate salt or a combination of acetic acid and its salt as a stabilizing agent.
  • the stabilizing agent significantly affects the stability of the formulation containing piperacillin or its salt, tazobactam or its salt, and dexamethasone phosphate or its salt. That is, when an acetate salt or a combination of acetic acid and its salt is added as a stabilizing agent, the formation of degradation products in an aqueous medium is remarkably reduced.
  • the pharmaceutical composition according to the present invention may be applied to the eye, ear, nose, skin, etc.; preferably formulated into an otic formulation form.
  • the pharmaceutically acceptable salt of piperacillin may be a conventional salt derived from alkali metal, including sodium salt, etc.
  • the pharmaceutically acceptable salt of piperacillin may be piperacillin sodium.
  • the concentration of piperacillin or its pharmaceutically acceptable salt may be a therapeutically effective amount range, preferably 1.0 to 20.0 %(w/v) based on the total composition. The use of piperacillin in the concentration exceeding 20.0 %(w/v) may bring about changes in the physical appearance, such as browning or precipitation during the storage.
  • the pharmaceutically acceptable salt of tazobactam may be a conventional salt derived from alkali metal, including sodium salt, etc.
  • the pharmaceutically acceptable salt of tazobactam may be tazobactam sodium.
  • the concentration of tazobactam or its pharmaceutically acceptable salt may be a therapeutically effective amount range, preferably 0.125 to 2.5 %(w/v) based on the total composition.
  • tazobactam may be used in a weight ratio of about 1/8, based on the amount of piperacillin.
  • the pharmaceutically acceptable salt of dexamethasone phosphate may be a conventional metal salt, such as dexamethasone monosodium phosphate, dexamethasone disodium phosphate, etc.
  • the pharmaceutically acceptable salt of dexamethasone phosphate may be dexamethasone disodium phosphate.
  • the concentration of dexamethasone phosphate or its pharmaceutically acceptable salt may be a therapeutically effective amount range, preferably 0.05 to 0.5 %(w/v) based on the total composition.
  • the pharmaceutical composition of the present invention may comprise piperacillin sodium, tazobactam sodium, dexamethasone disodium phosphate, and an acetate salt or a combination of acetic acid and its salt as a stabilizing agent.
  • the acetate salt includes a conventional salt, such as sodium acetate, calcium acetate, or potassium acetate.
  • Each salt may be an anhydrous form, a monohydrate form, a dihydrate form, and a trihydrate form, which can be used in the present invention without limitation.
  • the pharmaceutical composition of the present invention which obtained by using said stabilizing agent, may have a pH in the range of from 5.5 to 7.0. If necessary, the pharmaceutical composition of the present invention may further comprise hydrochloric acid or sodium hydroxide as a pH adjusting agent.
  • the pharmaceutical composition according to the present invention can be used not only in a single administration, but also in multiple administrations for long duration along with being stored at the cold condition (i.e., 2 to 8 °C).
  • the pharmaceutical composition may have a unit dosage form consisting of a first compartment comprising piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, dexamethasone phosphate or its pharmaceutically acceptable salt, and an acetate salt or a combination of acetic acid and its salt as a stabilizing agent; and a second compartment comprising water (for example, water for injection, de-ionized water).
  • the pharmaceutical composition may have a unit dosage form consisting of a first compartment comprising piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, and dexamethasone phosphate or its pharmaceutically acceptable salt; and a second compartment comprising water (for example, water for injection, de-ionized water) and an acetate salt or a combination of acetic acid and its salt as a stabilizing agent.
  • the first compartment may be in a vial form, and the second compartment may be in a plastic reservoir form.
  • the first compartment may comprise a simple mixture of piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, dexamethasone phosphate or its pharmaceutically acceptable salt, and an acetate salt or a combination of acetic acid and its salt; or a simple mixture of piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, and dexamethasone phosphate or its pharmaceutically acceptable salt.
  • the first compartment may comprise a lyophilized product thereof.
  • the first compartment may comprise a solid obtained by lyophilizing an aqueous solution comprising piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, dexamethasone phosphate or its pharmaceutically acceptable salt, and an acetate salt or a combination of acetic acid and its salt; or a solid obtained by lyophilizing an aqueous solution comprising piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, and dexamethasone phosphate or its pharmaceutically acceptable salt.
  • the second compartment may further comprise hydrochloric acid or sodium hydroxide as a pH adjusting agent, in addition to water (for example, water for injection) or in addition to a mixture of water (for example, water for injection) and an acetate salt or a combination of acetic acid and its salt.
  • the second compartment may further comprise a preservative of 0.001 to 0.18 %(w/v), based on the total composition.
  • the preservative may be one or more selected from methylparaben, ethylparaben, propylparaben (including isopropylparaben), isobutylparaben, etc.
  • a pharmaceutical composition for topical administration consisting of a first compartment comprising 4.0 %(w/v) of piperacillin sodium, 0.5 %(w/v) of tazobactam sodium, 0.1 %(w/v) of dexamethasone disodium phosphate, 0.003 %(w/v) of acetic acid, and 0.128 %(w/v) of sodium acetate; and a second compartment comprising 0.026 %(w/v) of methylparaben and 0.014 %(w/v) of propylparaben in water for injection.
  • a pharmaceutical composition for topical administration consisting of a first compartment comprising 5.0 %(w/v) of piperacillin sodium, 0.625 %(w/v) of tazobactam sodium, 0.1 %(w/v) of dexamethasone disodium phosphate, 0.003 %(w/v) of acetic acid, and 0.128 %(w/v) of sodium acetate; and a second compartment comprising 0.026 %(w/v) of methylparaben and 0.014 %(w/v) of propylparaben in water for injection.
  • a pharmaceutical composition for topical administration consisting of a first compartment comprising 8.0 %(w/v) of piperacillin sodium, 1.0 %(w/v) of tazobactam sodium, 0.1 %(w/v) of dexamethasone disodium phosphate, 0.003 %(w/v) of acetic acid, and 0.128 %(w/v) of sodium acetate; and a second compartment comprising 0.026 %(w/v) of methylparaben and 0.014 %(w/v) of propylparaben in water for injection.
  • a pharmaceutical composition for topical administration consisting of a first compartment comprising 20.0 %(w/v) of piperacillin sodium, 2.5 %(w/v) of tazobactam sodium, 0.1 %(w/v) of dexamethasone disodium phosphate, 0.003 %(w/v) of acetic acid, and 0.128 %(w/v) of sodium acetate; and a second compartment comprising 0.026 %(w/v) of methylparaben and 0.014 %(w/v) of propylparaben in water for injection.
  • a pharmaceutical composition for topical administration consisting of a first compartment comprising 4.0 %(w/v) of piperacillin sodium, 0.5 %(w/v) of tazobactam sodium, 0.1 %(w/v) of dexamethasone disodium phosphate, 0.003 %(w/v) of acetic acid, and 0.128 %(w/v) of sodium acetate; and a second compartment comprising 0.026 %(w/v) of methylparaben, 0.014 %(w/v) of propylparaben, and hydrochloric acid or sodium hydroxide as a pH adjusting agent in water for injection.
  • a pharmaceutical composition for topical administration consisting of a first compartment comprising 4.0 %(w/v) of piperacillin sodium, 0.5 %(w/v) of tazobactam sodium, and 0.1 %(w/v) of dexamethasone disodium phosphate; and a second compartment comprising 0.003 %(w/v) of acetic acid, 0.128 %(w/v) of sodium acetate, 0.026 %(w/v) of methylparaben and 0.014 %(w/v) of propylparaben in water for injection.
  • a pharmaceutical composition for topical administration consisting of a first compartment comprising 4.0 %(w/v) of piperacillin sodium, 0.5 %(w/v) of tazobactam sodium, and 0.1 %(w/v) of dexamethasone disodium phosphate; and a second compartment comprising 0.003 %(w/v) of acetic acid, 0.128 %(w/v) of sodium acetate, 0.026 %(w/v) of methylparaben, 0.014 %(w/v) of propylparaben, and hydrochloric acid or sodium hydroxide as a pH adjusting agent in water for injection.
  • Example 1 Preparation of pharmaceutical compositions consisting of a first compartment and a second compartment
  • compositions for topical administration comprising piperacillin sodium, tazobactam sodium, dexamethasone disodium phosphate, acetic acid and sodium acetate were prepared according to the components and amounts shown in Table 1.
  • the amounts of Table 1 represent in the amount based on the solution obtained by mixing the first compartment and the second compartment [%(w/v)].
  • Piperacillin sodium and tazobactam sodium were completely dissolved in water for injection (900 mL). While stirring the resulting solution, dexamethasone disodium phosphate was added thereto and then completely dissolved. While stirring the resulting solution, acetic acid and sodium acetate was added thereto and then completely dissolved. After the volume of the solution was adjusted to 1,000 mL with water for injection, the solution was stirred for about 30 minutes. The resulting each solution was subject to sterile filtration, decanted into sterilized vials, and then lyophilized. Each vial was closed with a rubber stopper and then sealed with a one-touch aluminum cap.
  • Example 1-5 the final pH of the solution was adjusted to about 6.0 with 0.01N hydrochloric acid and 0.01N sodium hydroxide. The resulting each solution was subject to sterile filtration, decanted into sterilized plastic reservoirs, each of which was then closed with a sterilized plastic sealing cap.
  • Example 2 Preparation of pharmaceutical compositions consisting of a first compartment and a second compartment
  • compositions for topical administration comprising piperacillin sodium, tazobactam sodium, dexamethasone disodium phosphate, acetic acid and sodium acetate were prepared according to the components and amounts shown in Table 2.
  • the amounts of Table 2 represent in the amount based on the solution obtained by mixing the first compartment and the second compartment [%(w/v)].
  • Piperacillin sodium and tazobactam sodium were completely dissolved in water for injection (900 mL). While stirring the resulting solution, dexamethasone disodium phosphate was added thereto and then completely dissolved. After the volume of the solution was adjusted to 1,000 mL with water for injection, the solution was stirred for about 30 minutes. The resulting each solution was subject to sterile filtration, decanted into sterilized vials, and then lyophilized. Each vial was closed with a rubber stopper and then sealed with a one-touch aluminum cap.
  • Example 2-2 Water for injection (900 mL) was heated to about 90°C and then propylparaben and methylparaben were dissolved therein. The resulting solution was cooled to room temperature. While stirring the resulting solution, acetic acid and sodium acetate was added thereto and then completely dissolved. After the volume of the solution was adjusted to 1,000 mL with water for injection, the solution was stirred for about 30 minutes. In case of Example 2-2, the final pH of the solution was adjusted to about 6.0 with 0.01N hydrochloric acid and 0.01N sodium hydroxide. The resulting each solution was subject to sterile filtration, decanted into sterilized plastic reservoirs, each of which was then closed with a sterilized plastic sealing cap.
  • the first compartments were prepared in the same procedures as in Example 1, except for using various stabilizing agents (and other excipients which may affect the pH) as shown in Table 3. Each resulting first compartment was dissolved in water for injection. Each concentration of Table 3 represents the concentration of the final formulation obtained by adding water for injection thereto. The initial amount of degradation products derived from piperacillin in each solution was measured; and then the amounts thereof were also measured after storing at the cold condition (about 2 to 8 °C) for 1 week and for 2 weeks. The results are shown in Table 3. There was observed no significant change in the amounts of degradation products derived from tazobactam and dexamethasone.
  • the first compartments were prepared in the same procedures as in Example 1, except for adjusting the pH as shown in Tables 4 and 5. Each resulting first compartment was dissolved in the second compartment. Each concentration of Tables 4 and 5 represents the concentration of the final formulation obtained by adding the second compartment thereto. The initial amount of degradation products derived from piperacillin in each solution was measured; and then the amount thereof was also measured after storing at the cold condition (about 2 to 8 °C) for 2 weeks. The results are shown in Tables 4 and 5. There was observed no significant change in the amounts of degradation products derived from tazobactam and dexamethasone.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a pharmaceutical composition for topical administration, comprising piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, dexamethasone phosphate or its pharmaceutically acceptable salt, and an acetate salt or a combination of acetic acid and its salt as a stabilizing agent. The pharmaceutical composition of the present invention may be formulated into a reconstitutable formulation form, which can be rapidly reconstituted. The pharmaceutical composition of the present invention shows minimized degradation product formation at the cold condition for long duration (e.g., about 2 weeks), thereby providing excellent stability. Therefore, the pharmaceutical composition according to the present invention can be used not only in a single administration, but also in multiple administrations for long duration.

Description

PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION COMPRISING PIPERACILLIN OR ITS SALT, TAZOBACTAM OR ITS SALT AND DEXAMETHASONE PHOSPHATE OR ITS SALT
The present invention relates to a pharmaceutical composition for topical administration comprising piperacillin or its salt, tazobactam or its salt and dexamethasone phosphate or its salt.
A pharmaceutical composition containing piperacillin (or piperacillin sodium) and tazobactam (or tazobactam sodium) is commercially available under the trademark ZosynTM. The composition, which is useful for intravenous administration as antibiotics for inpatients, has a lyophilized injection form. The lyophilized injection is administered by dissolving in water for injection, physiological saline, dextrose injection, etc., and the prepared solution should be used within 24 hours, at room temperature.
US Patent No. 6,207,661 has disclosed a premixed liquid composition comprising piperacillin sodium, tazobactam sodium, and sodium citrate as a buffer. The premixed liquid composition is stored under lyophilization. The stored lyophilized mixture is thawed (if necessary, a diluent is added thereto) and then parenterally administered to patients. And also, International Patent Publication No. WO2004/091666 has disclosed a pharmaceutical composition comprising piperacillin sodium; tazobactam sodium; an aminocarboxylic acid chelating agent such as ethylenediaminetetraacetic acid (EDTA) or its salt; a citrate salt as a buffer; and optionally an aminoglycoside.
Meanwhile, dexamethasone phosphate is a corticosteroid having potent anti-inflammatory activity. Especially, dexamethasone phosphate is useful for treating allergic diseases, skin disorders, inflammatory eye disease, and otitis externa/otitis media. It has been reported that a combination therapy of an antibiotic and a steroid provides therapeutic improvement, in various researches (Baum JL, et al., Am J Ophthalmol 1974;80:513-7; Barza M. et al., Infect Dis Clin North Am 1989;3:533-49; Schulman JA, et al., Retina 1992; 12:336-40; Meredith TA, et al., Ophthalmology 1990;108:857-60; Maxwell DP Jr, et al., Ophthalmology 1990;98:1370-5 etc.). Therefore, it is expected that a pharmaceutical composition containing piperacillin or its salt, tazobactam or its salt, and dexamethasone phosphate or its salt as active ingredients can be used as a formulation for topical administration which is applicable for treating or inhibiting bacterial infections in the eyes, ears, nose, or skin.
In order to design a pharmaceutical formulation for topical administration containing a combination of piperacillin or its salt, tazobactam or its salt, and dexamethasone phosphate or its salt, the formulation requires ensuring acceptable stability in an aqueous medium such as water for injection, physiological saline, dextrose injection, over the treatment duration. However, when piperacillin or its salt, tazobactam or its salt, and dexamethasone phosphate or its salt are mixed in the aqueous medium and then stored under the cold condition, degradation products are formed exceeding the acceptable criteria thereof in about 1 week, thereby being difficult to reuse over the treatment duration.
The present inventors carried out various researches in order to develop a stable pharmaceutical composition for topical administration comprising piperacillin or its salt, tazobactam or its salt, and dexamethasone phosphate or its salt, in which degradation product formation is minimized over the treatment duration. The present inventors found that a stabilizing agent (or a buffer agent) significantly affects the stability of the formulation containing piperacillin or its salt, tazobactam or its salt, and dexamethasone phosphate or its salt. Especially, the present inventors found that, if piperacillin or its salt, tazobactam or its salt, and dexamethasone phosphate or its salt were formulated into a reconstitutable formulation form having two compartments (e.g., a first vial or a second plastic reservoir) along with using an acetate salt or a combination of acetic acid and its salt as a stabilizing agent, rapid reconstitution was accomplished; and also degradation product formation was minimized at the cold condition for long duration (e.g., about 2 weeks), thereby providing excellent stability.
Therefore, it is an object of the present invention to provide a stable pharmaceutical composition for topical administration comprising piperacillin or its salt, tazobactam or its salt, and dexamethasone phosphate or its salt as active ingredients, along with an acetate salt or a combination of acetic acid and its salt as a stabilizing agent.
In accordance with an aspect of the present invention, there is provided a pharmaceutical composition for topical administration, comprising piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, dexamethasone phosphate or its pharmaceutically acceptable salt, and an acetate salt or a combination of acetic acid and its salt as a stabilizing agent.
In an embodiment of the present invention, the pharmaceutical composition may have a unit dosage form consisting of a first compartment comprising piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, dexamethasone phosphate or its pharmaceutically acceptable salt, and an acetate salt or a combination of acetic acid and its salt as a stabilizing agent; and a second compartment comprising water.
In another embodiment of the present invention, the pharmaceutical composition may have a unit dosage form consisting of a first compartment comprising piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, and dexamethasone phosphate or its pharmaceutically acceptable salt; and a second compartment comprising water and an acetate salt or a combination of acetic acid and its salt as a stabilizing agent.
It is found by the present invention that the stabilizing agent (or buffer agent) significantly affects the stability of the formulation containing piperacillin or its salt, tazobactam or its salt, and dexamethasone phosphate or its salt. Especially, it is found by the present invention that, if piperacillin or its salt, tazobactam or its salt, and dexamethasone phosphate or its salt are formulated into a reconstitutable formulation form having two compartments (e.g., a first vial or a second plastic reservoir) along with using an acetate salt or a combination of acetic acid and its salt as a stabilizing agent, rapid reconstitution is accomplished; and also degradation product formation is minimized at the cold condition for long duration (e.g., about 2 weeks), thereby providing excellent stability. Therefore, the pharmaceutical composition according to the present invention can be used not only in a single administration, but also in multiple administrations for long duration along with being stored at the cold condition (i.e., 2 to 8 ℃).
The present invention provides a pharmaceutical composition for topical administration, comprising piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, dexamethasone phosphate or its pharmaceutically acceptable salt, and an acetate salt or a combination of acetic acid and its salt as a stabilizing agent.
It is found by the present invention that the stabilizing agent (or buffer agent) significantly affects the stability of the formulation containing piperacillin or its salt, tazobactam or its salt, and dexamethasone phosphate or its salt. That is, when an acetate salt or a combination of acetic acid and its salt is added as a stabilizing agent, the formation of degradation products in an aqueous medium is remarkably reduced. The pharmaceutical composition according to the present invention may be applied to the eye, ear, nose, skin, etc.; preferably formulated into an otic formulation form.
In the pharmaceutical composition according to the present invention, the pharmaceutically acceptable salt of piperacillin may be a conventional salt derived from alkali metal, including sodium salt, etc. Preferably, the pharmaceutically acceptable salt of piperacillin may be piperacillin sodium. The concentration of piperacillin or its pharmaceutically acceptable salt may be a therapeutically effective amount range, preferably 1.0 to 20.0 %(w/v) based on the total composition. The use of piperacillin in the concentration exceeding 20.0 %(w/v) may bring about changes in the physical appearance, such as browning or precipitation during the storage.
The pharmaceutically acceptable salt of tazobactam may be a conventional salt derived from alkali metal, including sodium salt, etc. Preferably, the pharmaceutically acceptable salt of tazobactam may be tazobactam sodium. The concentration of tazobactam or its pharmaceutically acceptable salt may be a therapeutically effective amount range, preferably 0.125 to 2.5 %(w/v) based on the total composition. Typically, tazobactam may be used in a weight ratio of about 1/8, based on the amount of piperacillin.
And also, the pharmaceutically acceptable salt of dexamethasone phosphate may be a conventional metal salt, such as dexamethasone monosodium phosphate, dexamethasone disodium phosphate, etc. Preferably, the pharmaceutically acceptable salt of dexamethasone phosphate may be dexamethasone disodium phosphate. The concentration of dexamethasone phosphate or its pharmaceutically acceptable salt may be a therapeutically effective amount range, preferably 0.05 to 0.5 %(w/v) based on the total composition.
In an embodiment, the pharmaceutical composition of the present invention may comprise piperacillin sodium, tazobactam sodium, dexamethasone disodium phosphate, and an acetate salt or a combination of acetic acid and its salt as a stabilizing agent.
The acetate salt includes a conventional salt, such as sodium acetate, calcium acetate, or potassium acetate. Each salt may be an anhydrous form, a monohydrate form, a dihydrate form, and a trihydrate form, which can be used in the present invention without limitation. The pharmaceutical composition of the present invention, which obtained by using said stabilizing agent, may have a pH in the range of from 5.5 to 7.0. If necessary, the pharmaceutical composition of the present invention may further comprise hydrochloric acid or sodium hydroxide as a pH adjusting agent.
It is found by the present invention that, if piperacillin or its salt, tazobactam or its salt, and dexamethasone phosphate or its salt were formulated into a reconstitutable formulation form having two compartments (e.g., a first vial or a second plastic reservoir) along with using an acetate salt or a combination of acetic acid and its salt as a stabilizing agent as mentioned in the above, rapid reconstitution is accomplished; and also degradation product formation is minimized at the cold condition for long duration (e.g., about 2 weeks), thereby providing excellent stability. Therefore, the pharmaceutical composition according to the present invention can be used not only in a single administration, but also in multiple administrations for long duration along with being stored at the cold condition (i.e., 2 to 8 ℃).
Therefore, in an embodiment of the present invention, the pharmaceutical composition may have a unit dosage form consisting of a first compartment comprising piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, dexamethasone phosphate or its pharmaceutically acceptable salt, and an acetate salt or a combination of acetic acid and its salt as a stabilizing agent; and a second compartment comprising water (for example, water for injection, de-ionized water).
In another embodiment of the present invention, the pharmaceutical composition may have a unit dosage form consisting of a first compartment comprising piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, and dexamethasone phosphate or its pharmaceutically acceptable salt; and a second compartment comprising water (for example, water for injection, de-ionized water) and an acetate salt or a combination of acetic acid and its salt as a stabilizing agent.
The first compartment may be in a vial form, and the second compartment may be in a plastic reservoir form.
The first compartment may comprise a simple mixture of piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, dexamethasone phosphate or its pharmaceutically acceptable salt, and an acetate salt or a combination of acetic acid and its salt; or a simple mixture of piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, and dexamethasone phosphate or its pharmaceutically acceptable salt.
And also, in order to accurately adjust the amounts of piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, and dexamethasone phosphate or its pharmaceutically acceptable salt (and the acetate salt or the combination of acetic acid and its salt), the first compartment may comprise a lyophilized product thereof. That is, the first compartment may comprise a solid obtained by lyophilizing an aqueous solution comprising piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, dexamethasone phosphate or its pharmaceutically acceptable salt, and an acetate salt or a combination of acetic acid and its salt; or a solid obtained by lyophilizing an aqueous solution comprising piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, and dexamethasone phosphate or its pharmaceutically acceptable salt.
The second compartment may further comprise hydrochloric acid or sodium hydroxide as a pH adjusting agent, in addition to water (for example, water for injection) or in addition to a mixture of water (for example, water for injection) and an acetate salt or a combination of acetic acid and its salt. And also, the second compartment may further comprise a preservative of 0.001 to 0.18 %(w/v), based on the total composition. The preservative may be one or more selected from methylparaben, ethylparaben, propylparaben (including isopropylparaben), isobutylparaben, etc.
In an embodiment of the present invention, there is provided a pharmaceutical composition for topical administration consisting of a first compartment comprising 4.0 %(w/v) of piperacillin sodium, 0.5 %(w/v) of tazobactam sodium, 0.1 %(w/v) of dexamethasone disodium phosphate, 0.003 %(w/v) of acetic acid, and 0.128 %(w/v) of sodium acetate; and a second compartment comprising 0.026 %(w/v) of methylparaben and 0.014 %(w/v) of propylparaben in water for injection.
In another embodiment of the present invention, there is provided a pharmaceutical composition for topical administration consisting of a first compartment comprising 5.0 %(w/v) of piperacillin sodium, 0.625 %(w/v) of tazobactam sodium, 0.1 %(w/v) of dexamethasone disodium phosphate, 0.003 %(w/v) of acetic acid, and 0.128 %(w/v) of sodium acetate; and a second compartment comprising 0.026 %(w/v) of methylparaben and 0.014 %(w/v) of propylparaben in water for injection.
In still another embodiment of the present invention, there is provided a pharmaceutical composition for topical administration consisting of a first compartment comprising 8.0 %(w/v) of piperacillin sodium, 1.0 %(w/v) of tazobactam sodium, 0.1 %(w/v) of dexamethasone disodium phosphate, 0.003 %(w/v) of acetic acid, and 0.128 %(w/v) of sodium acetate; and a second compartment comprising 0.026 %(w/v) of methylparaben and 0.014 %(w/v) of propylparaben in water for injection.
In still another embodiment of the present invention, there is provided a pharmaceutical composition for topical administration consisting of a first compartment comprising 20.0 %(w/v) of piperacillin sodium, 2.5 %(w/v) of tazobactam sodium, 0.1 %(w/v) of dexamethasone disodium phosphate, 0.003 %(w/v) of acetic acid, and 0.128 %(w/v) of sodium acetate; and a second compartment comprising 0.026 %(w/v) of methylparaben and 0.014 %(w/v) of propylparaben in water for injection.
In still another embodiment of the present invention, there is provided a pharmaceutical composition for topical administration consisting of a first compartment comprising 4.0 %(w/v) of piperacillin sodium, 0.5 %(w/v) of tazobactam sodium, 0.1 %(w/v) of dexamethasone disodium phosphate, 0.003 %(w/v) of acetic acid, and 0.128 %(w/v) of sodium acetate; and a second compartment comprising 0.026 %(w/v) of methylparaben, 0.014 %(w/v) of propylparaben, and hydrochloric acid or sodium hydroxide as a pH adjusting agent in water for injection.
In still another embodiment of the present invention, there is provided a pharmaceutical composition for topical administration consisting of a first compartment comprising 4.0 %(w/v) of piperacillin sodium, 0.5 %(w/v) of tazobactam sodium, and 0.1 %(w/v) of dexamethasone disodium phosphate; and a second compartment comprising 0.003 %(w/v) of acetic acid, 0.128 %(w/v) of sodium acetate, 0.026 %(w/v) of methylparaben and 0.014 %(w/v) of propylparaben in water for injection.
In still another embodiment of the present invention, there is provided a pharmaceutical composition for topical administration consisting of a first compartment comprising 4.0 %(w/v) of piperacillin sodium, 0.5 %(w/v) of tazobactam sodium, and 0.1 %(w/v) of dexamethasone disodium phosphate; and a second compartment comprising 0.003 %(w/v) of acetic acid, 0.128 %(w/v) of sodium acetate, 0.026 %(w/v) of methylparaben, 0.014 %(w/v) of propylparaben, and hydrochloric acid or sodium hydroxide as a pH adjusting agent in water for injection.
The present invention will be described in further detail with reference to the following examples. These examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
Example 1: Preparation of pharmaceutical compositions consisting of a first compartment and a second compartment
Pharmaceutical compositions for topical administration comprising piperacillin sodium, tazobactam sodium, dexamethasone disodium phosphate, acetic acid and sodium acetate were prepared according to the components and amounts shown in Table 1. The amounts of Table 1 represent in the amount based on the solution obtained by mixing the first compartment and the second compartment [%(w/v)].
Table 1
Compartment Component Amount [%(w/v)]
1-1 1-2 1-3 1-4 1-5
First compartment Piperacillin sodium 4.0 5.0 8.0 20.0 4.0
Tazobactam sodium 0.5 0.625 1.0 2.5 0.5
Dexamethasone disodium phosphate 0.1 0.1 0.1 0.1 0.1
Acetic acid 0.003 0.003 0.003 0.003 0.003
Sodium acetate 0.128 0.128 0.128 0.128 0.128
Second compartment Methylparaben 0.026 0.026 0.026 0.026 0.026
Propylparaben 0.014 0.014 0.014 0.014 0.014
Hydrochloric acid or sodium hydroxide - - - - q.s.
Water for injection q.s. q.s. q.s. q.s. q.s.
pH 5.98 5.99 5.90 5.88 6.06
< Preparation of a first compartment >
Piperacillin sodium and tazobactam sodium were completely dissolved in water for injection (900 mL). While stirring the resulting solution, dexamethasone disodium phosphate was added thereto and then completely dissolved. While stirring the resulting solution, acetic acid and sodium acetate was added thereto and then completely dissolved. After the volume of the solution was adjusted to 1,000 mL with water for injection, the solution was stirred for about 30 minutes. The resulting each solution was subject to sterile filtration, decanted into sterilized vials, and then lyophilized. Each vial was closed with a rubber stopper and then sealed with a one-touch aluminum cap.
< Preparation of a second compartment >
Water for injection (900 mL) was heated to about 90℃ and then propylparaben and methylparaben were dissolved therein. The resulting solution was cooled to room temperature. After the volume of the solution was adjusted to 1,000 mL with water for injection, the solution was stirred for about 30 minutes. In case of Example 1-5, the final pH of the solution was adjusted to about 6.0 with 0.01N hydrochloric acid and 0.01N sodium hydroxide. The resulting each solution was subject to sterile filtration, decanted into sterilized plastic reservoirs, each of which was then closed with a sterilized plastic sealing cap.
Example 2: Preparation of pharmaceutical compositions consisting of a first compartment and a second compartment
Pharmaceutical compositions for topical administration comprising piperacillin sodium, tazobactam sodium, dexamethasone disodium phosphate, acetic acid and sodium acetate were prepared according to the components and amounts shown in Table 2. The amounts of Table 2 represent in the amount based on the solution obtained by mixing the first compartment and the second compartment [%(w/v)].
Table 2
Compartment Component Amount [%(w/v)]
2-1 2-2
First compartment Piperacillin sodium 4.0 4.0
Tazobactam sodium 0.5 0.5
Dexamethasone disodium phosphate 0.1 0.1
Second compartment Acetic acid 0.003 0.003
Sodium acetate 0.128 0.128
Methylparaben 0.026 0.026
Propylparaben 0.014 0.014
Hydrochloric acid or sodium hydroxide - q.s.
Water for injection q.s. q.s.
pH 5.98 6.06
< Preparation of a first compartment >
Piperacillin sodium and tazobactam sodium were completely dissolved in water for injection (900 mL). While stirring the resulting solution, dexamethasone disodium phosphate was added thereto and then completely dissolved. After the volume of the solution was adjusted to 1,000 mL with water for injection, the solution was stirred for about 30 minutes. The resulting each solution was subject to sterile filtration, decanted into sterilized vials, and then lyophilized. Each vial was closed with a rubber stopper and then sealed with a one-touch aluminum cap.
< Preparation of a second compartment >
Water for injection (900 mL) was heated to about 90℃ and then propylparaben and methylparaben were dissolved therein. The resulting solution was cooled to room temperature. While stirring the resulting solution, acetic acid and sodium acetate was added thereto and then completely dissolved. After the volume of the solution was adjusted to 1,000 mL with water for injection, the solution was stirred for about 30 minutes. In case of Example 2-2, the final pH of the solution was adjusted to about 6.0 with 0.01N hydrochloric acid and 0.01N sodium hydroxide. The resulting each solution was subject to sterile filtration, decanted into sterilized plastic reservoirs, each of which was then closed with a sterilized plastic sealing cap.
Example 3: Evaluation of stability according to stabilizing agents
The first compartments were prepared in the same procedures as in Example 1, except for using various stabilizing agents (and other excipients which may affect the pH) as shown in Table 3. Each resulting first compartment was dissolved in water for injection. Each concentration of Table 3 represents the concentration of the final formulation obtained by adding water for injection thereto. The initial amount of degradation products derived from piperacillin in each solution was measured; and then the amounts thereof were also measured after storing at the cold condition (about 2 to 8 ℃) for 1 week and for 2 weeks. The results are shown in Table 3. There was observed no significant change in the amounts of degradation products derived from tazobactam and dexamethasone.
Table 3
Component [%(w/v)] 3-1 3-2 3-3 3-4 3-5 3-6
Piperacillin sodium 5 5 5 5 5 5
Tazobactam sodium 0.625 0.625 0.625 0.625 0.625 0.625
Dexamethasone disodium phosphate - 0.1 0.1 0.1 0.1 0.1
Sodium edetate 0.01 - - - - -
Citric acid - - 0.024 - - -
Sodium citrate q.s. - 0.257 - - -
Acetic acid - - - 0.0032 - -
Sodium acetate - - - 0.128 - -
Sodium monohydrogen phosphate - - - - 0.12 -
Sodium dihydrogen phosphate - - - - 0.032 -
Sulfuric acid - - - - - 0.001
Sodium sulfate - - - - - 0.142
Ionic strength (mM) - - 10 10 10 10
pH 6.63 5.99 6.59 6.08 5.95 5.89
Amount of degradation products Initial 2.04% 2.02% 2.02% 2.07% 2.08% 2.22%
After 1 week 3.17% 2.41% 2.28% 2.35% 2.34% 2.40%
After 2 weeks 4.64% 4.33% 4.02% 3.55% 4.09% 4.30%
From the results of Table 3, it can be seen that the use of other stabilizing agents such as citric acid/citrate salt, sulfuric acid/sulfate salt, etc. remarkably increased the formation of degradation products derived from piperacillin. In contrast, the use of acetic acid/acetate salt as a stabilizing agent significantly reduced the formation of degradation products derived from piperacillin.
Example 4: Evaluation of stability according to pHs
The first compartments were prepared in the same procedures as in Example 1, except for adjusting the pH as shown in Tables 4 and 5. Each resulting first compartment was dissolved in the second compartment. Each concentration of Tables 4 and 5 represents the concentration of the final formulation obtained by adding the second compartment thereto. The initial amount of degradation products derived from piperacillin in each solution was measured; and then the amount thereof was also measured after storing at the cold condition (about 2 to 8 ℃) for 2 weeks. The results are shown in Tables 4 and 5. There was observed no significant change in the amounts of degradation products derived from tazobactam and dexamethasone.
Table 4
Component [%(w/v)] 4-1 4-2 4-3 4-4 4-5 4-6
Piperacillin sodium 8 8 8 8 8 8
Tazobactam sodium 1 1 1 1 1 1
Dexamethasone disodium phosphate 0.1 0.1 0.1 0.1 0.1 0.1
Acetic acid 0.021 0.015 0.013 0.009 0.004 0.003
Sodium acetate 0.087 0.100 0.106 0.115 0.127 0.129
Methylparaben 0.026 0.026 0.026 0.026 0.026 0.026
Propylparaben 0.014 0.014 0.014 0.014 0.014 0.014
Water for injection q.s. q.s. q.s. q.s. q.s. q.s.
pH 5.0 5.2 5.3 5.5 5.9 6.0
Amount of degradation products Initial 2.05% 2.13% 2.22% 2.21% 2.24% 2.04%
After 2 weeks 5.40% 5.14% 4.61% 3.97% 3.29% 3.13%
Table 5
Component [%(w/v)] 4-7 4-8 4-9 4-10 4-11 4-12
Piperacillin sodium 8 8 8 8 8 8
Tazobactam sodium 1 1 1 1 1 1
Dexamethasone disodium phosphate 0.1 0.1 0.1 0.1 0.1 0.1
Acetic acid 0.002 0.002 0.001 - - -
Sodium acetate 0.130 0.131 0.134 0.268 0.543 0.816
Methylparaben 0.026 0.026 0.026 0.026 0.026 0.026
Propylparaben 0.014 0.014 0.014 0.014 0.014 0.014
Water for injection q.s. q.s. q.s. q.s. q.s. q.s.
pH 6.1 6.2 6.5 7.0 7.5 8.0
Amount of degradation products Initial 2.10% 2.10% 2.06% 2.05% 2.02% 1.97%
After 2 weeks 3.29% 3.20% 3.14% 3.20% 4.15% 5.91%
From the results of Tables 4 and 5, it can be seen that the solutions having the pH in the range of 5.5 to 7.0 meet the USP criterion [Pharmacopeial Forum, 37(2) In-Process Revision, Piperacillin and Tazobactam for Injection, Procedure 2] (i.e., not more than 4.0 % of total degradation products), while the solutions having the other pH ranges do not meet the USP criterion.

Claims (23)

  1. A pharmaceutical composition for topical administration, comprising piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, dexamethasone phosphate or its pharmaceutically acceptable salt, and an acetate salt or a combination of acetic acid and its salt as a stabilizing agent.
  2. The pharmaceutical composition for topical administration according to claim 1, comprising piperacillin sodium, tazobactam sodium, dexamethasone disodium phosphate, and an acetate salt or a combination of acetic acid and its salt as a stabilizing agent.
  3. The pharmaceutical composition for topical administration according to claim 1, wherein the concentration of piperacillin or its pharmaceutically acceptable salt is 1.0 to 20.0 %(w/v) based on the total composition.
  4. The pharmaceutical composition for topical administration according to claim 1, wherein the concentration of tazobactam or its pharmaceutically acceptable salt is 0.125 to 2.5 %(w/v) based on the total composition.
  5. The pharmaceutical composition for topical administration according to claim 1, wherein the concentration of dexamethasone phosphate or its pharmaceutically acceptable salt is 0.05 to 0.5 %(w/v) based on the total composition.
  6. The pharmaceutical composition for topical administration according to claim 1, wherein the acetate salt is sodium acetate, calcium acetate, or potassium acetate.
  7. The pharmaceutical composition for topical administration according to claim 1, having a pH in the range of from 5.5 to 7.0.
  8. The pharmaceutical composition for topical administration according to claim 1, further comprising hydrochloric acid or sodium hydroxide as a pH adjusting agent.
  9. The pharmaceutical composition for topical administration according to any one of claims 1 to 8, having a unit dosage form consisting of
    a first compartment comprising piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, dexamethasone phosphate or its pharmaceutically acceptable salt, and an acetate salt or a combination of acetic acid and its salt as a stabilizing agent; and
    a second compartment comprising water.
  10. The pharmaceutical composition for topical administration according to claim 9, wherein the first compartment comprises a solid obtained by lyophilizing an aqueous solution comprising piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, dexamethasone phosphate or its pharmaceutically acceptable salt, and an acetate salt or a combination of acetic acid and its salt.
  11. The pharmaceutical composition for topical administration according to claim 9, wherein the second compartment further comprises hydrochloric acid or sodium hydroxide as a pH adjusting agent.
  12. The pharmaceutical composition for topical administration according to claim 9, wherein the second compartment further comprises a preservative of 0.001 to 0.18 %(w/v) based on the total composition.
  13. A pharmaceutical composition for topical administration consisting of
    a first compartment comprising 4.0 %(w/v) of piperacillin sodium, 0.5 %(w/v) of tazobactam sodium, 0.1 %(w/v) of dexamethasone disodium phosphate, 0.003 %(w/v) of acetic acid, and 0.128 %(w/v) of sodium acetate; and
    a second compartment comprising 0.026 %(w/v) of methylparaben and 0.014 %(w/v) of propylparaben in water for injection.
  14. A pharmaceutical composition for topical administration consisting of
    a first compartment comprising 5.0 %(w/v) of piperacillin sodium, 0.625 %(w/v) of tazobactam sodium, 0.1 %(w/v) of dexamethasone disodium phosphate, 0.003 %(w/v) of acetic acid, and 0.128 %(w/v) of sodium acetate; and
    a second compartment comprising 0.026 %(w/v) of methylparaben and 0.014 %(w/v) of propylparaben in water for injection.
  15. A pharmaceutical composition for topical administration consisting of
    a first compartment comprising 8.0 %(w/v) of piperacillin sodium, 1.0 %(w/v) of tazobactam sodium, 0.1 %(w/v) of dexamethasone disodium phosphate, 0.003 %(w/v) of acetic acid, and 0.128 %(w/v) of sodium acetate; and
    a second compartment comprising 0.026 %(w/v) of methylparaben and 0.014 %(w/v) of propylparaben in water for injection.
  16. A pharmaceutical composition for topical administration consisting of
    a first compartment comprising 20.0 %(w/v) of piperacillin sodium, 2.5 %(w/v) of tazobactam sodium, 0.1 %(w/v) of dexamethasone disodium phosphate, 0.003 %(w/v) of acetic acid, and 0.128 %(w/v) of sodium acetate; and
    a second compartment comprising 0.026 %(w/v) of methylparaben and 0.014 %(w/v) of propylparaben in water for injection.
  17. A pharmaceutical composition for topical administration consisting of
    a first compartment comprising 4.0 %(w/v) of piperacillin sodium, 0.5 %(w/v) of tazobactam sodium, 0.1 %(w/v) of dexamethasone disodium phosphate, 0.003 %(w/v) of acetic acid, and 0.128 %(w/v) of sodium acetate; and
    a second compartment comprising 0.026 %(w/v) of methylparaben, 0.014 %(w/v) of propylparaben, and hydrochloric acid or sodium hydroxide as a pH adjusting agent in water for injection.
  18. The pharmaceutical composition for topical administration according to any one of claims 1 to 8, having a unit dosage form consisting of
    a first compartment comprising piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, and dexamethasone phosphate or its pharmaceutically acceptable salt; and
    a second compartment comprising water and an acetate salt or a combination of acetic acid and its salt as a stabilizing agent.
  19. The pharmaceutical composition for topical administration according to claim 18, wherein the first compartment comprises a solid obtained by lyophilizing an aqueous solution comprising piperacillin or its pharmaceutically acceptable salt, tazobactam or its pharmaceutically acceptable salt, and dexamethasone phosphate or its pharmaceutically acceptable salt.
  20. The pharmaceutical composition for topical administration according to claim 18, wherein the second compartment further comprises hydrochloric acid or sodium hydroxide as a pH adjusting agent.
  21. The pharmaceutical composition for topical administration according to claim 18, wherein the second compartment further comprises a preservative of 0.001 to 0.18 %(w/v) based on the total composition.
  22. A pharmaceutical composition for topical administration consisting of
    a first compartment comprising 4.0 %(w/v) of piperacillin sodium, 0.5 %(w/v) of tazobactam sodium, and 0.1 %(w/v) of dexamethasone disodium phosphate; and
    a second compartment comprising 0.003 %(w/v) of acetic acid, 0.128 %(w/v) of sodium acetate, 0.026 %(w/v) of methylparaben and 0.014 %(w/v) of propylparaben in water for injection.
  23. A pharmaceutical composition for topical administration consisting of
    a first compartment comprising 4.0 %(w/v) of piperacillin sodium, 0.5 %(w/v) of tazobactam sodium, and 0.1 %(w/v) of dexamethasone disodium phosphate; and
    a second compartment comprising 0.003 %(w/v) of acetic acid, 0.128 %(w/v) of sodium acetate, 0.026 %(w/v) of methylparaben, 0.014 %(w/v) of propylparaben, and hydrochloric acid or sodium hydroxide as a pH adjusting agent in water for injection.
PCT/KR2013/009020 2012-10-19 2013-10-10 Pharmaceutical composition for topical administration comprising piperacillin or its salt, tazobactam or its salt and dexamethasone phosphate or its salt WO2014061937A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2012-0116373 2012-10-19
KR1020120116373A KR101816798B1 (en) 2012-10-19 2012-10-19 Pharmaceutical composition for topical administration comprising piperacillin or its salt, tazobactam or its salt and dexamethasone phosphate or its salt

Publications (1)

Publication Number Publication Date
WO2014061937A1 true WO2014061937A1 (en) 2014-04-24

Family

ID=50488451

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/009020 WO2014061937A1 (en) 2012-10-19 2013-10-10 Pharmaceutical composition for topical administration comprising piperacillin or its salt, tazobactam or its salt and dexamethasone phosphate or its salt

Country Status (2)

Country Link
KR (1) KR101816798B1 (en)
WO (1) WO2014061937A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102065236B1 (en) 2018-02-12 2020-01-10 아주대학교산학협력단 Once-daily complex orally fast-disintegrating tablet comprising immediated release dexamethasone and sustained release ondansetron and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060234995A1 (en) * 2003-04-14 2006-10-19 Cohen Jonathan M Compositions containing piperacillin and tazobactam useful for injection
US20070054889A1 (en) * 2005-09-02 2007-03-08 Acs Dobfar S.P.A. Injectable sterile pharmaceutical formulation containing at least two active principles
WO2010111641A2 (en) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
US20110044917A1 (en) * 2008-03-31 2011-02-24 Alessandro Tosetti Dental composition for treating peri-implantitis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060234995A1 (en) * 2003-04-14 2006-10-19 Cohen Jonathan M Compositions containing piperacillin and tazobactam useful for injection
US20070054889A1 (en) * 2005-09-02 2007-03-08 Acs Dobfar S.P.A. Injectable sterile pharmaceutical formulation containing at least two active principles
US20110044917A1 (en) * 2008-03-31 2011-02-24 Alessandro Tosetti Dental composition for treating peri-implantitis
WO2010111641A2 (en) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RUSSO, S. ET AL.: "Dexamethasone-netilmicin: a new ophthalmic steroid-antibiotic combination. Efficacy and safety after cataract surgery", EYE, vol. 21, 2007, pages 58 - 64 *

Also Published As

Publication number Publication date
KR101816798B1 (en) 2018-01-10
KR20140052122A (en) 2014-05-07

Similar Documents

Publication Publication Date Title
KR100595956B1 (en) Aqueous liquid preparations
US8975284B2 (en) Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents
US20110160261A2 (en) Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents
EP0604570B1 (en) Compositions containing quinolone antibiotics and sulfonate of polystyrol
WO2012091357A2 (en) Composition for prevention of nausea or vomiting
WO2014061937A1 (en) Pharmaceutical composition for topical administration comprising piperacillin or its salt, tazobactam or its salt and dexamethasone phosphate or its salt
WO2012074237A2 (en) Liquid medicine composition including dorzolamide and brimonidine for ophthalmology
US4093716A (en) Compositions containing 5-amino-5-deoxythymidine and pharmaceutically acceptable salts thereof
KR20180085496A (en) Lyophilized formulation comprising piperacillin or its salt and tazobactam or its salt
WO2014010924A1 (en) Pharmaceutical composition for topical administration comprising vancomycin or its salt and dexamethasone phosphate or its salt
US5084276A (en) Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation
US20090247752A1 (en) Gatifloxacin-containing aqueous liquid preparation, its production and method for suppressing formation of precipitate during storage at lower temperature and at the time of freezing and thawing of the aqueous liquid preparation
WO2016028002A1 (en) Process for preparing ertapenem-containing lyophilized formulation
KR20210126515A (en) Composition for preventing and treating pulmonary hypertension comprising niclosamide
CN105939720B (en) Composition effective against viral conjunctivitis
IE54625B1 (en) Enhanced resorption antibacterial compositions
EP0814813B1 (en) Use of penciclovir for the treatment of human herpes-virus-8
JP2944759B2 (en) Antimicrobial composition
WO2019168289A1 (en) Eye drops in form of solution comprising benzopyran derivative or pharmaceutically acceptable salt thereof
Laxson 13 Chapter Osmotic Agents
JPS63264418A (en) Stabilized ophthalmic composition
KR20230107624A (en) Ophthalmic composition containing levofloxacin and ketorolac, preparation method and use thereof
CN112007031A (en) Ophthalmic preparation
JPH051075A (en) Aqueous solution stably containing carbapenem compound
US20040023983A1 (en) Methods of use of fluoroquinolone compounds against pathogenic helicobacter bacteria

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13848057

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13848057

Country of ref document: EP

Kind code of ref document: A1